• The Journal of Korean Physical Therapy
• /
• 제14권4호
• /
• pp.100-118
• /
• 2002

This study was to investigate the effect of long-term high intensity endurance training on the activation of antioxidation enzyme activity, lipid peroxidation and lipoprotein metabolism. 15 subjects were divided into, endurance exercise + antioxidation Vitamin supplement(n=5), endurance exercise(n=5), and the control(n=5) groups. The endurance exercise groups(endurance exercise + antioxidation Vitamin supplement and endurance exercise) had 12 week of endurance exercise program. The antioxidation Vitamin supplement group was taken a Vitamin C tablet with 1000mg/day and Vitamin E tablet with 671.14mg/day right after lunch. The results obtained from this study were as follows; 1. Looking at the changes of SOD, Endurance exercise+antioxidation Vitamin supplement group and endurance exercise groups showed the significantly greater decrease in the activation of SOD after 12 weeks of all-out exercise. 2. Looking at the changes of CAT, Endurance exercise+antioxidation Vitamin supplement group revealed subjects tended to increase CAT after all-out exercise although statistically non-significant. Endurance exercise+antioxidation Vitamin supplement group showed the significantly greater increase in the activation of CAT after 12 weeks treatment for all-out exercise. 3. Looking at the changes of GPX, Endurance exercise+antioxidation Vitamin supplement group revealed subjects tended to increase GPX for the rest and after all-out exercise although statistically non-significant. Endurance exercise+antioxidation Vitamin supplement group showed the significantly greater increase in the activation of GPX after 12 weeks treatment for all-out exercise. 4. The MDA change showed the significant decrease after 6 weeks, after 12 weeks for the all-out exercise of Endurance exercise + antioxidation Vitamin supplement group. 5. There was non-significant change in lipoprotein metabolism for the rest and after all-out exercise.

• 한국임상약학회지
• /
• 제25권1호
• /
• pp.56-58
• /
• 2015

Summary: We report the first hepatic adverse effect of tosufloxacin tosylate in a muscle invasive bladder cancer patient with normal liver functions and with scheduling to undergo a surgical operation for a neobladder. Tosufloxacin tosylate 150 mg was administered to a 57-year-old man who maintained transurethral resection of bladder tumor (TUR-BT) postoperative multiple medications. His labs presented significant increases in alanine amino transferase (ALT) and aspartate amino transferase (AST) levels with 2-week compliance of 150 mg tablet three times a day. After discontinuing tosufloxacin tosylate, the levels slowly decreased and completely returned to normal ranges without any intervention in a few weeks. The Naranjo Causality Algorithm indicates a probable relationship between increased ALT and tosufloxacin. The patient was to have the second surgical operation as scheduled after getting normal range of ATL level. Therefore, tosufloxacin should be avoided in patients at risk for having liver dysfunctions or diseases if the patients have a schedule for any operation. Background: Tosufloxacin tosylate has been shown to have favorable benefits as an antibiotic. Tosufloxacin tosylate may be considered to have the adverse effects such as nauseas, vomiting, diarrhea, abdominal pain, stomatitis, tendonitis, tendon rupture, headache, dizziness, drowsiness, insomnia, weakness, agitation including hemolysis in the event of glucose-6-phosphate dehydrogenase deficiency as other fluoroquinolones. More severe adverse reactions of tosufloxacin tosylate over the above common adverse effects of fluoroquinolones were thrombocytopenia and nephritis. It also is not well known that tosufloxacin can cause hepatic problem. Here the study reports the first hepatic reaction from tosufloxacin and might arouse heath care providers' attention to appropriate drug choice for patients.

• Biomolecules & Therapeutics
• /
• 제19권2호
• /
• pp.248-254
• /
• 2011

Biotransformation of pharmacologically inactive lactone prodrug simvastatin (SV) into pharmacologically active simvastatin ${\beta}$-hydroxy acid (SVA) exhibits inter-species differences due to variations in amount and activity of esterase enzymes. In this study, we investigated the pharmacokinetics (PK) of SV and its metabolite SVA following oral doses of SV from controlled-release (CR) tablets and immediate-release (IR) tablets in rodent and canine animal models that features different esterase activity. In rat PK study, no SV was detected in plasma for both formulations due to rapid hydrolysis of SV into SVA by plasma esterase. Besides, no significant differences in PK parameters of SV or SVA were observed between both species. In dog PK study, the relative oral bioavailability of CR tablets in terms of SV was 72.3% compared to IR tablets. Regarding formulation differences in dogs, CR tablets exhibited significantly lower $C_{max}$ (p<0.05), and higher $T_{max}$ (p<0.01) and MRT (p<0.01) for both SV and SVA compared to IR tablets. Accordingly, CR tablets of SV with prolonged drug release profiles in both species might be a potential candidate for a more effective delivery of SV with reduced side effects. Besides, similar PK parameters of SV and SVA in both species despite variation in enzyme activities suggested involvement of equally potent biotransformation pathways in these animal species.

• Journal of Microbiology and Biotechnology
• /
• 제31권4호
• /
• pp.592-600
• /
• 2021

Probiotics can be processed into a powder, tablet, or capsule form for easy intake. They are exposed to frequent stresses not only during complex processing steps, but also in the human body after intake. For this reason, various coating agents that promote probiotic bacterial stability in the intestinal environment have been developed. Silk fibroin (SF) is a material used in a variety of fields from drug delivery systems to enzyme immobilization and has potential as a coating agent for probiotics. In this study, we investigated this potential by coating probiotic strains with 0.1% or 1% water-soluble calcium (WSC), 1% SF, and 10% trehalose. Under simulated gastrointestinal conditions, cell viability, cell surface hydrophobicity, and cell adhesion to intestinal epithelial cells were then measured. The survival ratio after freeze-drying was highest upon addition of 0.1% WSC. The probiotic bacteria coated with SF showed improved survival by more than 10.0% under simulated gastric conditions and 4.8% under simulated intestinal conditions. Moreover, the cell adhesion to intestinal epithelial cells was elevated by 1.0-36.0%. Our results indicate that SF has positive effects on enhancing the survival and adhesion capacity of bacterial strains under environmental stresses, thus demonstrating its potential as a suitable coating agent to stabilize probiotics throughout processing, packaging, storage and consumption.

• 한국식품저장유통학회지
• /
• 제19권6호
• /
• pp.909-918
• /
• 2012

유근피에 함유된 페놀성 물질은 70% ethanol을 용매로 하여 12시간 추출하였을 때 $17.9{\pm}1.0\;mg/g$으로 가장 많이 용출되었다. 유근피 추출물의 항산화력을 측정한 결과 전자공여능은 $50{\mu}g/mL$ 이상의 phenolic 농도에서 물추출물과 70% ethanol 추출물 모두에서 80% 이상의 높은 전자공여능이 확인되었다. ABTS radical cation decolorization을 측정한 결과 유근피는 물과 70% ethanol 추출물에서 $96.8{\pm}2.9%$의 높은 항산화활성이 측정되었으며, antioxidant protection factor 측정에서는 물추출물과 에탄올 추출물 모두 $200{\mu}g/mL$의 phenolic 농도에서 BHA 보다 높은 2.5 PF의 높은 항산화력이 확인되었다. 유근피 추출물의 thiobarbituric acid reactive substance를 측정한 결과 물 추출물과 에탄올 추출물 전 농도에서 약 80%의 높은 항산화 효과를 나타내었다. 유근피 추출물의 항고혈압 효과를 살펴보기 위하여 angiotensin converting enzyme 저해활성을 측정한 결과 물 추출물에서 약 50%, 70% ethanol 추출물에서 58.5%의 저해활성을 나타내었으며, $200{\mu}g/mL$ phenolics의 처리농도에서 물 추출물이 77.4%, 70% ethanol 추출물에서 90.6%의 저해활성을 나타내었다. 유근피 추출물의 항관절염 효과를 살펴보기 위하여 xanthin oxidase 저해 활성을 측정한 결과 물 추출물에서는 억제 효과를 관찰할 수 없었고, 70% ethanol 추출물에서 30%의 억제효과를 나타내었으며, $200{\mu}g/mL$ phenolics의 처리 농도에서 48.1%의 억제력을 나타내었다. 유근피 추출물의 염증 억제효과를 측정하기 위하여 hyaluronidase 저해활성을 확인한 결과 물 추출물과 ethanol 추출물에서 70% 이상의 높은 저해 양상을 나타내었으며, $50{\mu}g/mL$ phenolics의 낮은 농도로 처리하였을 경우에도 80%의 항염증효과를 나타내었고, 처리한 phenolic compound의 농도가 높아질수록 억제효과가 높아져 농도 의존적인 양상을 나타내었다. 기능성 식품으로의 활용을 위한 방안으로 유근피 추출물을 함유한 tablet(정제)를 개발하고, 개발된 제품의 관능평가를 실시한 결과 색깔의 관능 평점이 8.3으로 평가되었고, 맛과 향은 8.8과 8.6의 높은 관능평가 점수를 획득하였으며, 전체적인 기호도 역시 8.7점으로 높은 평가를 받았다.

• 한국식품영양학회지
• /
• 제26권1호
• /
• pp.137-145
• /
• 2013

동아(冬瓜, wax gourd, Benincase hispida) 추출물과 프로바이오틱 유산균(Lactobacillus casei와 Bifidobacterium bifidum)(이하 유산균이라 한다)의 생리활성을 분석하였다. 동아 추출물은 안기오텐신전환효소의 활성을 47.9%, 티로시나제의 활성을 13.2% 저해하였고, 항산화 활성을 23.4% 나타냈다. 설사 증세자 120명에게 동아 추출물 제제를 72시간 복용시킨 결과 117명이 개선되었고, 6~12시간째에 개선율이 가장 높았다. 개선율은 80%가 치료되는 상태를 기준하였다. 유산균 제제는 안기오텐신전환효소의 활성을 21.4% 저해하였다. 설사 증세자 120명에게 유산균 제제를 72시간 복용시킨 결과 108명이 개선되었고, 24시간째에 개선율이 가장 높았다. 이들 결과를 바탕으로, 과민성대장증후군 개선을 위한 동아 추출물과 유산균을 함유한 제제(tablet)를 개발하였다. 이 제품은 안기오텐신전환효소의 활성을 27.1% 저해하였고, 항산화 활성을 20.3% 나타냈다. 인체폐암 A549 세포에 100 ${\mu}g/m{\ell}$ 및 250 ${\mu}g/m{\ell}$ 농도로 이 제제를 가하여 24시간 반응시킨 결과, 세포 증식을 67% 억제하였고, 동아 추출물 제제나 프로바이오틱 유산균 제제 단독으로 작용시킨 것보다 억제율이 높았다. 또 이 제제를 인체대장암 HCT116 세포에 100 ${\mu}g/m{\ell}$ 농도로 가한 결과, 24시간 후 세포 증식이 70% 억제되었고, 동아 추출물 제제나 유산균 제제 단독으로 작용시킨 것보다 개선율과 개선 속도가 높았다. 이 제제를 설사형, 변비형, 일반형의 과민성대장증후군 증세자 164명에게 72시간 복용시킨 결과 100% 개선시켰으며, 개선율은 3~6시간째에 가장 높았고, 동아 추출물 제제나 유산균 제제 단독으로 사용한 것보다 개선율과 개선속도가 높았다.